FibroScan is now available in 11 United Digestive clinics, improving early detection and care for liver disease
Echosens, the leader in non-invasive liver diagnostics, has partnered with United Digestive, the largest gastroenterology platform in the Southeast, to bring FibroScan to 11 clinics across Georgia and Florida. This collaboration enhances United Digestive’s ability to detect liver disease earlier and develop tailored care plans based on patient risk factors.
Health Technology Insights: Johnson & Johnson Seeks EMA Approval to Extend AKEEGA Use for Prostate Cancer
United Digestive has implemented FibroScan as an in-clinic diagnostic service, allowing providers to risk-stratify their patients earlier and assess their liver health quickly, painlessly, and cost-effectively. The tool has become a valuable addition to routine care for patients with obesity, diabetes, metabolic syndromes, and those on long-term medications that may affect the liver.
“We see the impact of obesity and metabolic dysfunctions every day in our clinics. FibroScan allows us to identify at-risk patients earlier and determine the most appropriate care pathways, whether that’s nutrition counseling, lifestyle modifications, referrals to hepatologists, or additional tests and treatments,” says John Suh, MD, MPH, gastroenterologist and chief medical officer at United Digestive. “Occasionally, current therapies are not appropriate for a patient. FibroScan can help identify those who may be better suited for enrollment in clinical research studies evaluating new treatment approaches.”
Health Technology Insights: AAMI Aligns With National Academy of Medicine AI Code of Conduct
Early detection of liver disease is critical, as symptoms typically do not appear until the condition has significantly progressed. FibroScan can help detect advanced liver disease with excellent diagnostic performance, often years before clinical symptoms or complications develop. For fatty liver detection and quantification, FibroScan has been shown to be especially advantageous in early or mild steatosis and in patients with coexisting fibrosis, where ultrasound sensitivity drops. It also serves as a strong motivational tool for patients affected by steatotic liver disease, helping to drive awareness and adherence to care plans. Integrating FibroScan into routine visits helps ensure that more patients, especially those with metabolic risk factors, receive timely intervention.
Marc Sonenshine, MD, gastroenterologist and executive vice president for clinical initiatives at United Digestive, adds, “FibroScan is changing how we manage liver health—it’s enabling earlier diagnoses and, in turn, earlier interventions. The actionable insights from FibroScan enhance patient education, drive more meaningful engagement, and encourage long-term adherence to care plans. The demand has been significant, and it’s clear how valuable this tool has become in our clinics.”
The implementation across 11 clinics represents a significant step in scaling access to liver health insights in Georgia and Florida. “This is what forward-thinking healthcare looks like—getting the right tools in the hands of providers so they can act early and decisively, ultimately improving outcomes for patients,” says Jon Gingrich, CEO of Echosens North America. “We admire United Digestive’s leadership in making non-invasive liver assessment both accessible and actionable in the clinic setting. We look forward to growing this partnership so that even more patients can take charge of their liver health.”
Health Technology Insights: ACA Pharma Secures Fast-track Approval For Eagle Pharmaceuticals’ Ryanodex In Macau
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
